PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 6, 2026Journal of the American College of Cardiology267 citations

3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds

View Full Paper
Dean J. Kereiakes
Dean J. KereiakesInterventional Cardiology
Stephen G. Ellis
Stephen G. EllisInterventional / Structural CardiologyCMChristopher MetzgerHolston Valley Medical Center

Key Points

Key points are not available for this paper at this time.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kereiakes et al. (2017) studied this question.

synapsesocial.com/papers/69fb0789b2ff0c89f6b91171https://doi.org/10.1016/j.jacc.2017.10.010
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 12-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy2017 · 209 citations
  2. 2Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice2017 · 27 citations
  3. 3A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis2016 · 160 citations
  4. 4Incidence and Imaging Outcomes of Acute Scaffold Disruption and Late Structural Discontinuity After Implantation of the Absorb Everolimus-Eluting Fully Bioresorbable Vascular Scaffold2014 · 116 citations
  5. 5OCT Assessment of the Long-Term Vascular Healing Response 5 Years After Everolimus-Eluting Bioresorbable Vascular Scaffold2014 · 108 citations